Citi says SMid biotechs alternative to large caps as it starts coverage
Citi has expanded its biopharmaceutical research coverage, initiating coverage on seven small- and mid-cap (SMid) biotechnology companies. Citi said SMid biotechs remain an attractive alternative to ...
BioNTech SE (NASDAQ:BNTX) Analysts Are Cutting Their Estimates: Here's What You Need To Know
BioNTech SE ( NASDAQ:BNTX ) just released its full-year report and things are looking bullish. Results overall ...
BioNTech initiated with a Buy at Citi
Citi analyst Geoff Meacham initiated coverage of BioNTech (BNTX) with a Buy rating and $145 price target Healthcare policy remains a key ...